Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNYZ) Amortization of Deferred Charges (2016 - 2025)

Historic Amortization of Deferred Charges for Ligand Pharmaceuticals (LGNYZ) over the last 14 years, with Q3 2025 value amounting to $447000.0.

  • Ligand Pharmaceuticals' Amortization of Deferred Charges rose 23358.21% to $447000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $880000.0, marking a year-over-year increase of 12278.48%. This contributed to the annual value of $486000.0 for FY2024, which is 10250.0% up from last year.
  • Latest data reveals that Ligand Pharmaceuticals reported Amortization of Deferred Charges of $447000.0 as of Q3 2025, which was up 23358.21% from $125000.0 recorded in Q2 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Amortization of Deferred Charges registered a high of $4.9 million during Q1 2021, and its lowest value of $64000.0 during Q2 2023.
  • Its 5-year average for Amortization of Deferred Charges is $1.0 million, with a median of $137000.0 in 2022.
  • Per our database at Business Quant, Ligand Pharmaceuticals' Amortization of Deferred Charges tumbled by 9751.89% in 2022 and then soared by 23358.21% in 2025.
  • Quarter analysis of 5 years shows Ligand Pharmaceuticals' Amortization of Deferred Charges stood at $3.8 million in 2021, then tumbled by 97.52% to $95000.0 in 2022, then fell by 14.74% to $81000.0 in 2023, then soared by 112.35% to $172000.0 in 2024, then skyrocketed by 159.88% to $447000.0 in 2025.
  • Its Amortization of Deferred Charges stands at $447000.0 for Q3 2025, versus $125000.0 for Q2 2025 and $136000.0 for Q1 2025.